|
EP3341007B1
(en)
|
2015-08-28 |
2020-12-23 |
Cornell University |
Malt1 inhibitors and uses thereof
|
|
CA3003820A1
(en)
*
|
2015-11-13 |
2017-05-18 |
Novartis Ag |
Novel pyrazolo pyrimidine derivatives
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2018165385A1
(en)
|
2017-03-08 |
2018-09-13 |
Cornell University |
Inhibitors of malt1 and uses thereof
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP3679027A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydrobenzimidazolones
|
|
WO2019043214A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
glutarimide
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
WO2019099868A2
(en)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
|
US11571427B2
(en)
|
2017-12-28 |
2023-02-07 |
The General Hospital Corporation |
Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
|
|
WO2019191112A1
(en)
|
2018-03-26 |
2019-10-03 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
BR112020018006A2
(pt)
|
2018-04-12 |
2021-01-12 |
Bayer Aktiengesellschaft |
Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1h-1,2,4-triazol-5-il]etil}benzamida e os derivados correspondentes de piridina-carboxamida como pesticidas
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
CA3096404A1
(en)
|
2018-04-23 |
2019-10-31 |
Celgene Corporation |
Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
|
|
DK3784661T3
(da)
|
2018-04-25 |
2024-02-12 |
Bayer Ag |
Hidtil ukendte heteroaryl-triazol- og heteroaryl-tetrazol-forbindelser som pesticider
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN110615779B
(zh)
*
|
2018-06-20 |
2023-03-24 |
上海科技大学 |
制备来那度胺衍生物的方法
|
|
WO2020111087A1
(ja)
*
|
2018-11-28 |
2020-06-04 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
|
US12233356B2
(en)
|
2019-03-21 |
2025-02-25 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
CN113747925B
(zh)
|
2019-03-21 |
2024-10-15 |
隆萨销售股份公司 |
胞外囊泡缀合物及其用途
|
|
WO2020263935A1
(en)
|
2019-06-24 |
2020-12-30 |
Dana-Farber Cancer Institute, Inc. |
Hck degraders and uses thereof
|
|
PH12022550166A1
(en)
|
2019-07-23 |
2022-11-14 |
Bayer Ag |
Novel heteroaryl-triazole compounds as pesticides
|
|
TW202128664A
(zh)
|
2019-10-09 |
2021-08-01 |
德商拜耳廠股份有限公司 |
作為除害劑之新穎雜芳基三唑化合物
|
|
AU2020407244A1
(en)
*
|
2019-12-20 |
2022-07-28 |
Abbvie Inc. |
Protein tyrosine phosphatase degraders and methods of use thereof
|
|
BR112022012684A2
(pt)
*
|
2019-12-27 |
2023-03-07 |
Schroedinger Inc |
Compostos cíclicos e métodos de uso dos mesmos
|
|
IL297486A
(en)
*
|
2020-04-23 |
2022-12-01 |
Univ Iowa Res Found |
Gper proteolytic targeting chimeras
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
US20230192685A1
(en)
*
|
2020-05-27 |
2023-06-22 |
Takeda Pharmaceutical Company Limited |
Method for producing heterocyclic compound
|
|
JP2023530937A
(ja)
*
|
2020-06-17 |
2023-07-20 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｅ３－リガーゼ系の共動員を介した標的化された異常なα－シヌクレイン種ならびに誘導されたユビキチン化およびプロテアソームクリアランス
|
|
WO2021262969A1
(en)
|
2020-06-24 |
2021-12-30 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
WO2022101676A1
(en)
*
|
2020-11-12 |
2022-05-19 |
Monopteros Therapeutics,Inc. |
Materials and methods of treating cancer
|
|
EP4277901A1
(en)
|
2021-01-13 |
2023-11-22 |
Monte Rosa Therapeutics, Inc. |
Isoindolinone compounds
|
|
US12123053B2
(en)
|
2021-01-29 |
2024-10-22 |
Eurofins Discoverx Corporation |
Molecular glue screening assays and methods for practicing same
|
|
US20250059196A1
(en)
|
2021-12-30 |
2025-02-20 |
Shanghai Hansoh Biomedical Co., Ltd. |
Tricyclic derivative inhibitor, preparation method therefor, and application thereof
|
|
EP4466268A4
(en)
*
|
2022-01-18 |
2025-12-10 |
Aurigene Oncology Ltd |
Substituted bicyclic heterocyclics used as MALT-1 inhibitors
|
|
TW202340198A
(zh)
*
|
2022-01-28 |
2023-10-16 |
大陸商上海齊魯製藥研究中心有限公司 |
靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
|
|
KR20240144146A
(ko)
|
2022-02-02 |
2024-10-02 |
오노 야꾸힝 고교 가부시키가이샤 |
Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
|
|
AU2023224879B2
(en)
*
|
2022-02-25 |
2025-10-09 |
Tegid Therapeutics, Inc. |
Protacs of malt1
|
|
KR20250021314A
(ko)
|
2022-06-06 |
2025-02-12 |
씨4 테라퓨틱스, 인코포레이티드 |
비시클릭-치환된 글루타르이미드 세레블론 결합제
|